Rubrik on its $752 Million IPO
Cooley advised Rubrik, the Zero Trust Data Security Company delivering data security and operational resilience for enterprises, on its $752 million initial public offering. Partners Jon Avina, Calise Cheng and Milson Yu led the Cooley team advising Rubrik.
Rapport Therapeutics on its $154 Million IPO
Cooley advised the underwriters in Rapport Therapeutics’ $154 million initial public offering. Partners Richard Segal, Divakar Gupta, Darah Protas and Ryan Sansom led the Cooley team. Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system disorders.
Boundless Bio on its $100 Million IPO
Cooley advised the underwriters in Boundless Bio’s $100 million initial public offering. Partners Charlie Kim, Denny Won and Charles Bair led the Cooley team. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene […]
Alumis on its $250 Million IPO and Private Placement
Cooley advised Alumis, a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases, on its $250 million initial public offering and private placement. Partners Dave Peinsipp, Kristin VanderPas and Lauren Creel led the Cooley team.
Alto Neuroscience on its $147.9 Million IPO
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering. Partners Div Gupta, Christina Roupas, Courtney Tygesson and Laurie Bauer led the Cooley team advising Alto.
CG Oncology on its $437 Million IPO
Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led […]
CARGO Therapeutics on its $281.3 Million IPO
Cooley advised the underwriters on CARGO Therapeutics’ $281.3 million initial public offering. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team advising the underwriters.
Lexeo Therapeutics on its $100 Million IPO
Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering. Partners Eric Blanchard, Peter Byrne and Div Gupta led the Cooley team advising Lexeo.
Abivax on its $235.8 Million IPO
Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Instacart on its $660 Million IPO
Cooley represented Instacart, the leading grocery technology company in North America, on its $660 million initial public offering. Partners Jon Avina, Rachel Proffitt, Jonie Kondracki and Milson Yu led the Cooley team advising Instacart.